Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab

Introduction: Secondary thyroid autoimmunity, especially Graves’ disease (GD), frequently develops in patients with multiple sclerosis (MS) following alemtuzumab treatment (ALTZ; anti-CD52). Thyroid eye disease (TED) can also develop, and rituximab (RTX; anti-CD20) is a suitable treatment. Case pr...

Full description

Bibliographic Details
Main Authors: Ilaria Muller, Sara Maioli, Mirco Armenti, Laura Porcaro, Nicola Currò, Elisabetta Iofrida, Lorenzo Pignataro, Jacopo Manso, Caterina Mian, Jens Geginat, Mario Salvi
Format: Article
Language:English
Published: Bioscientifica 2024-04-01
Series:European Thyroid Journal
Subjects:
thyroid eye disease
graves’ orbitopathy
immune reconstitution therapy
rituximab
alemtuzumab
lymphocyte depletion
Online Access:https://etj.bioscientifica.com/view/journals/etj/13/2/ETJ-23-0236.xml

Internet

https://etj.bioscientifica.com/view/journals/etj/13/2/ETJ-23-0236.xml

Similar Items